Cargando…
Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
BACKGROUND: Atopic dermatitis (AD) is a common skin disease, but treatment of this disease has been challenging. Dupilumab is a new biological agent for AD that has been proven to be safe and effective in clinical trials. Although dupilumab was approved for listing in China in June 2020, real-world...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984471/ https://www.ncbi.nlm.nih.gov/pubmed/35402441 http://dx.doi.org/10.3389/fmed.2022.838030 |